Introduction
In the developing embryo, the earliest hematopoietic activity is characterized by lineage-restricted progenitors that arise initially in the yolk sac prior to and independent of hematopoietic stem cells (HSCs) (1) (2) (3) (4) . In contrast, the first definitive HSCs -defined by their capacity for long-term, multilineage engraftment in adult recipients -are detected thereafter in arterial vessels, such as the dorsal aorta, of the region known as the aorta-gonad-mesonephros (AGM) (5) and subsequently home to the fetal liver, where HSCs undergo further maturation and significant proliferative expansion prior to seeding the marrow (6, 7) . Importantly, identifying the resident niche signals that distinctly support the specification and initial self-renewal of definitive HSCs could improve our ability to generate transplantable HSCs from pluripotent stem cells or reprogrammed cells, and thus have significant therapeutic implications.
The transition to definitive HSCs occurs from VE-cadherin + endothelial-like precursors called hemogenic endothelium (HE) in the context of the arterial vasculature via maturation through HSC precursors (8, 9) , suggesting the vascular niche provides signals for HSC induction from HE. While HE cells are phenotypically indistinguishable by most known surface markers from nonhemogenic endothelial cells (ECs), they express hematopoietic transcription factors, such as RUNX1, during the endothelial-to-HSC transition (10, 11) . Recently, this transition has been visualized in the dorsal aorta as clusters of hematopoietic cells (expressing initial hematopoietic markers c-KIT and CD41, followed by CD45) bud from the underlying endothelium within the vascular wall (12) (13) (14) , suggesting dynamic interactions between emerging hematopoietic cells and cells of the vascular niche regulate the process of HSC formation. Importantly, the niche must provide signals that not only promote HSC induction from HE, but subsequently limit lineage-restricted differentiation and promote HSC self-renewal. Notably, signals to support HSC amplification are present in AGM explant or reaggregation cultures ex vivo; These signals were shown to correlate with survival of ECs (15, 16) . The capacity of primary ECs from the paraaortic splanchnopleura (P-Sp) -the mesodermal precursor to the AGM region -to support HSC activity from adult BM during in vitro coculture was demonstrated by Li and colleagues (17) , while other studies have shown that stromal cell lines derived from the AGM region, some of which have endothelial properties, can support both embryonic and adult HSC maintenance in vitro (18) (19) (20) . Furthermore, previous studies from our labs and others have established a role for the vascular niche in supporting adult marrow-derived HSCs ex vivo (21) (22) (23) (24) . However, it has not previously been established whether an EC niche, such as from the AGM, is sufficient to induce the specification of bona fide, long-term engrafting HSCs from nonengrafting embryonic precursors, including HE, and support subsequent numerical expansion of embryonic-stage HSCs. Within the AGM, NOTCH signaling is essential for HSC development and is thought to be mediated by cell-to-cell interactions involving dynamic NOTCH receptor expression on hematopoietic Hematopoietic stem cells (HSCs) first emerge during embryonic development within vessels such as the dorsal aorta of the aorta-gonad-mesonephros (AGM) region, suggesting that signals from the vascular microenvironment are critical for HSC development. Here, we demonstrated that AGM-derived endothelial cells (ECs) engineered to constitutively express AKT (AGM AKT-ECs) can provide an in vitro niche that recapitulates embryonic HSC specification and amplification. Specifically, nonengrafting embryonic precursors, including the VE-cadherin-expressing population that lacks hematopoietic surface markers, cocultured with AGM AKT-ECs specified into long-term, adult-engrafting HSCs, establishing that a vascular niche is sufficient to induce the endothelial-to-HSC transition in vitro. Subsequent to hematopoietic induction, coculture with AGM AKT-ECs also substantially increased the numbers of HSCs derived from VE-cadherin + CD45
+ AGM hematopoietic cells, consistent with a role in supporting further HSC maturation and self-renewal. We also identified conditions that included NOTCH activation with an immobilized NOTCH ligand that were sufficient to amplify AGM-derived HSCs following their specification in the absence of AGM AKT-ECs. Together, these studies begin to define the critical niche components and resident signals required for HSC induction and self-renewal ex vivo, and thus provide insight for development of defined in vitro systems targeted toward HSC generation for therapeutic applications.
Endothelium and NOTCH specify and amplify aortagonad-mesonephros-derived hematopoietic stem cells Brandon K. Hadland, 1,2 Barbara Varnum-Finney, 1 Michael G. Poulos, 3, 4, 5 Randall T. Moon, 6, 7 Jason M. Butler, 3, 4, 5 Shahin Rafii, 3, 4, 7 and Irwin D. Bernstein conditions to study EC contribution to stem/progenitor cell niches in vitro (35) . AGM AKT-ECs express endothelial markers VE-cadherin, CD31, and FLK1 -as well as SCA-1 and low levels of CD34 -and lack expression of hematopoietic marker CD45 ( Figure 1B) . Furthermore, AGM AKT-ECs demonstrate relatively homogenous expression of NOTCH ligands, including Jagged1 (JAG1), Jagged2 (JAG2), Delta-like-1 (DLL1), and Delta-like-4 (DLL4) (characteristic of arterial endothelium), compared with more heterogeneous expression of NOTCH ligands on fresh AGM ECs (gated as VE-cadherin
) from dissected embryos ( Figure 1C ; control staining in Supplemental Figure 1 ; supplemental material available online with this article; doi:10.1172/JCI80137DS1). Although the population from which AGM AKT-ECs are derived may contain a small proportion of HE cells at the time they are isolated that cannot be distinguished by known surface markers, we observed no residual hematopoietic potential of the AGM AKTECs once established, as assayed by generation of phenotypic CD45 + cells, hematopoietic colony-forming potential, or transplantation assays following culture of AGM AKT-ECs alone with hematopoietic cytokines (AGM AKT-EC only), in experiments performed in parallel with coculture experiments described below ( Figure 2 and data not shown).
AGM-derived EC coculture induces HSCs from E9-E10 VE-cadherin
+ precursors. Previous studies demonstrated that HSC activity can be detected in the AGM at low frequency (3 mice engrafted from 112 embryos) as early as E10.5 (34-41 somite pairs [sp]) by direct transplantation to adult recipients (5). Prior to this stage, between E9 and E10, in vitro multipotent hematopoietic progenitors and precursors capable of engraftment into conditioned newborn mice can be detected in the VE-cadherin + and c-KIT + populations (36, 37) , suggesting that further maturation from precursors before E10.5 is required prior to attaining the capacity for multilineage engraftment into adult recipients. To determine whether AGM AKT-ECs can promote HSC induction from developmental precursors, we isolated VE-cadherin + cells from E9.5-E10 (25-32 sp) P-Sp/AGM for coculture in the presence of serum-free media (X-Vivo) and hematopoietic cytokines (TPO, SCF, IL3, FLT3L) ( Figure 2A ). Sorted E9.5-E10 VE-cadherin + cells gave rise visually to colonies of apparent hematopoietic cells during coculture on AGM AKT-ECs ( Figure 2B ). Hematopoietic identity of cells generated in coculture was confirmed by FACS demonstrating surface expression of the pan-hematopoietic marker CD45 + ( Figure 2C ). A subset of cells also expressed markers of myeloid lineage (Gr1 and F4/80), erythroid lineage (TER119), and stem/progenitor cells (LSK phenotype: SCA-1 + , c-KIT + , lineage marker-negative) (Supplemental Figure 2 ). Compared with the initial VE-cadherin + precursor population and with cells cultured under control conditions without ECs, cells cultured on AGM AKT-ECs generated enhanced numbers of total hematopoietic cells, LSK stem/progenitor cells, and colony-forming progenitors (Figure 2 , D and E). Most importantly, E9.5-E10 P-Sp/AGM VE-cadherin + cells cultured on AGM AKT-ECs also generated HSCs capable of high-level, multilineage engraftment at more than 20 weeks after transplant in peripheral blood (PB), BM, thymus, and spleen of transplanted adult congenic-strain mice. These HSCs were also capable of multilineage engraftment following transplantation into secondary recipients (Figure 2 , F and G, and Supplemental Figure 3A) . Similar highcells emerging from underlying ECs expressing NOTCH ligands (25) . Whereas NOTCH signaling is dispensable for the earlier yolk sac-derived primitive and erythromyeloid phases of hematopoiesis, knockout and chimeric analysis in murine embryos demonstrated that NOTCH1 signaling is required for definitive HSCs that can contribute to long-term multilineage hematopoiesis (26, 27) . In this context, NOTCH1 activation is known to play a role in arterial endothelial fate and in embryonic HSC specification mediated via downstream transcription factors such as GATA2, HES1, and RUNX1 (28) (29) (30) (31) . Notably, a recent study also suggests a function for NOTCH1 signaling supporting fetal liver HSCs (32), a unique period when HSCs are undergoing substantial proliferative expansion. Although canonical NOTCH signaling does not appear to be required for adult HSCs during homeostasis (33) , NOTCH2 activation may promote HSC self-renewal by limiting their differentiation under certain proliferative conditions, such as after BM injury (34) . Thus, NOTCH activation mediated by ligand expression within cells of various hematopoietic niches may play a role in supporting multiple phases of HSC development from specification to self-renewal. Further understanding of the effects of stage-specific NOTCH activation in nascent HSCs and their precursors from the AGM may increase our ability to generate HSCs ex vivo.
To dissect the niche requirements for embryonic HSC development, we describe here the use of ECs derived from the AGM as a substrate to recapitulate early HSC specification and amplification in vitro. We utilized primary AGM ECs in which constitutive AKT activation was induced to generate an in vitro vascular niche suitable for coculture in serum-free conditions, and show that AKT-activated AGM-derived ECs (AGM AKT-ECs) provide signals sufficient to promote induction of engrafting HSCs from nonengrafting embryo-derived precursors, including HE. Furthermore, these ECs enhance subsequent expansion of HSC numbers from specified VE-cadherin +
CD45
+ hematopoietic cells from the AGM. We further identified conditions with NOTCH activation, cytokines, and TGF-β inhibition that were sufficient to support an increase of AGM-derived, long-term HSCs but were insufficient in generating HSCs from HE. Altogether, these studies begin to deconstruct the necessary conditions to promote induction and self-renewal of HSCs ex vivo, which will further the goal of developing methods using defined reagents to generate HSCs in vitro for therapeutic purposes. Figure 3A ).
Results

AGM-derived
While these results suggested the capacity of AGM AKT-ECs to induce HSCs from HE in vitro, further validation was necessary to rule out the possibility of contamination of the VE-cadherin + c-KIT -population with HPCs. Thus, we also examined the potential of HE defined by absence of expression of CD41, the ear liest level, multilineage engraftment was observed from VE-cadherin + cells cultured with multiple, independently generated AGM AKTECs ( Figure 2H ). Furthermore, VE-cadherin + cells capable of generating HSCs with long-term, multilineage engraftment into adult mice were detected as early as E9 (13-20 somite pairs [sp]), following 7 days of coculture with AGM AKT-ECs ( Figure 2H ). In contrast, control cultures without ECs or on OP9, a stromal line that supports hematopoietic progenitor activity in culture (38) , did not produce engrafting cells (Figure 2 , F and H). As expected, freshly sorted, uncultured VE-cadherin + cells from E9.5-E10 P-Sp/AGM did not engraft adult recipients, nor did AGM AKT-ECs cultured alone under hematopoietic conditions without P-Sp/AGM cells ( Figure 2H ). Altogether, these results demonstrate that AGM AKTECs express niche factors capable of promoting HSC induction in vitro from nonengrafting VE-cadherin + precursors.
AGM-derived ECs coculture induces HSCs from E9-E10 HE.
Beginning after E9 in the P-Sp/AGM, the VE-cadherin + population contains both c-KIT -ECs as well as c-KIT + hematopoietic progenitor cells (HPCs), which also express low levels of the early Since NOTCH is an essential pathway involved in the endothelial-to-hematopoietic transition in the P-Sp/AGM at this stage, we also tested whether blocking NOTCH signaling could inhibit hematopoietic induction from HE upon AGM AKT-EC coculture. Consistent with a requirement for NOTCH, we show that generation of CD45 + cells from VE-cadherin + CD41 -CD45 -HE cultured on AGM AKT-ECs was significantly reduced by the addition of the gamma-secretase inhibitor DAPT, which blocks NOTCH activation by preventing cleavage of the intracellular domain required for downstream signaling through NOTCH receptors ( Figure 3E ). We also tested hematopoietic-supportive OP9 stromal cells (endogenously expressing NOTCH ligand JAG1) or OP9 cells engineered to express NOTCH ligands DLL1 or DLL4 (Supplemental Figure   marker of HPCs with clonal colony-forming capacity in the P-Sp/ AGM, and CD45, a pan-hematopoietic marker expressed subsequent to CD41 in P-Sp/AGM HPCs. We observed long-term, multilineage primary and secondary engraftment from either VEcadherin The HE-to-hematopoietic transition is dependent on extrinsic niche signals that include NOTCH pathway activation mediated by NOTCH ligand-expressing stromal cells. In the absence of such inductive signals, HE by definition should lack direct clonal hematopoietic activity. Consistent with this, VE-cadherin
-CD45 -HE cells sorted from E9.5-E10 P-Sp/AGM contain no direct CFU progenitor activity in methylcellulose assays and are unable to generate CD45 + hematopoietic cells or CFU progenitors following culture 1B) and found that each was capable of CD45 + hematopoietic cell generation from E9.5-E10 P-Sp/AGM-derived HE (Supplemental Figure 5A ). However, in contrast to AGM AKT-ECs, coculture of HE with OP9 stroma-expressing NOTCH ligands did not induce engrafting hematopoietic cells (Supplemental Figure 5B) .
Altogether, these results are consistent with the known requirement for NOTCH activation during the endothelial-to-hematopoietic transition. However, whereas NOTCH ligand-expressing OP9 stromal cells can promote induction of hematopoietic activity from AGM/P-Sp HE, AGM AKT-ECs provide additional signals to promote their induction into definitive HSCs capable of highlevel, multilineage engraftment in adult recipients.
AGM-derived EC coculture amplifies HSCs from E11 AGM VEcadherin + CD45
+ hematopoietic cells. Subsequent to their induction 
CD45
-cells (Supplemental Figure 6 ), a population + hematopoietic cells promotes expansion of phenotypic and functional hematopoietic stem/progenitor populations with multilineage hematopoietic activity.
We next sought to determine whether cells generated on NOTCH ligand from AGM-derived hematopoietic cells were also capable of short-and long-term multilineage engraftment in vivo. E11 VE-cadherin + CD45 + AGM cells cultured 5 days on Delta1 ext-IgG or control hIgG, with 4GF+SB, were transplanted at one embryo equivalent of starting cells into lethally irradiated congenic-strain adult mice together with a small dose of congenic BM cells. For some experiments, freshly sorted CD45 + VEcadherin + cells, uncultured, were also transplanted at 1 embryo equivalent per mouse to measure engraftment of the starting population. + hematopoietic cells. NOTCH1 is expressed in the emerging hematopoietic clusters in the P-Sp/ AGM (31) and is required for initial HSC generation (26, 27) . We have shown that induction of hematopoeitic cells from E9.5 AGM/ P-Sp-derived HE can be blocked by preventing NOTCH pathway activation with gamma-secretase inhibitor treatment during AGM AKT-EC coculture ( Figure 3E ). We observed surface expression of NOTCH1, as well as NOTCH2, in specified AGM hematopoietic progenitors (expressing hematopoietic surface markers: E9.5 c-KIT and CD41; E11 CD45) ( Figure 5A ). Importantly, NOTCH1 and NOTCH2 surface expression in nascent AGM hematopoietic cells suggests that, following the initial requirement for NOTCH1 in hematopoietic induction in the AGM/P-Sp, HSCs may continue to be receptive to NOTCH pathway activation mediated by ligandexpressing ECs. To test whether AGM-derived HSCs require the NOTCH pathway during the phase of expansion in AGM AKT-EC coculture, we cultured E11 VE-cadherin + CD45
+ cells on AGM AKT-ECs with gamma-secretase inhibitor DAPT. We observed significantly reduced LSK and LSK-SLAM cell numbers, but not total or myeloid cell numbers, in cultures with DAPT compared with control (DMSO-treated) cultures ( Figure 5B), suggesting a specific effect on hematopoietic stem/progenitor cells at this stage.
Based on these findings, we then tested whether activation of NOTCH signaling by immobilized ligand was sufficient to amplify long-term HSCs from E11 AGM-derived VE-cadherin + CD45
+ cells in the absence of EC stroma. To activate NOTCH signaling, we employed Delta1 (Delta1 ext-IgG ), consisting of the extracellular domain of human Delta1 fused to the Fc domain of human IgG1 (hIgG1) (43, 44) . We have previously shown that culture of murine adult BM HSCs with immobilized Delta1 ext-IgG and hematopoietic cytokines inhibits myeloid differentiation in vitro and generates increased numbers of LSK multipotent progenitors capable of short-term, multilineage engraftment (44). We here cultured E11 AGM-derived VE-cadherin + CD45
+ cells on Delta1 ext-IgG or control hIgG, in media containing FBS and hematopoietic cytokines SCF, FLT3L, IL-6, and TPO (4GF) ( Figure 6A ). Based on previously reported studies suggesting an inhibitory effect of the TGF-β pathway during AGM-stage hematopoiesis (45), we found that the addition of a small molecule TGF-β inhibitor (SB431542 or LY364947) was essential in order to generate outgrowth of LSK cells (Supplemental Figure 7) . E11 VE-cadherin + CD45 + AGMderived cells cultured with hematopoietic cytokines and TGF-β inhibitor SB431542 (4GF+SB) on either Delta1 ext-IgG or hIgG, were mostly VE-cadherin -after 5 days, consistent with phenotypic maturation from the AGM to later developmental stages of hematopoiesis where VE-cadherin expression is lost (ref. 41 and Figure 6B HPCs already expressing hematopoietic markers c-KIT and CD41. However, we also show in this study the capacity of AGM AKT-ECs to induce HSCs from HE contained within the VE-cadherin + population yet lacking expression of hematopoietic surface markers or direct clonal hematopoietic activity. Thus, we provide the first evidence, to our knowledge, that an EC niche is sufficient to recapitulate the embryonic HE-to-HSC transition ex vivo. Notably, a recent study in zebrafish suggests an essential in vivo role for a subset of somite-derived ECs in the dorsal aorta in supporting HSC induction from adjacent HE (48) , further promoting the concept that ECs provide essential niche signals for HSC induction.
Importantly, further studies of the EC coculture system will facilitate the determination of paracrine signals essential for HSC generation. Since AKT activation was necessary in these studies to permit AGM-derived ECs to grow in serum-free conditions suitable for coculture with HSCs/precursors, it is impossible to rule out that some properties of AGM AKT-ECs that allow for support of HSC generation may be induced by AKT activation. In this regard, AKT activation was previously shown to be involved in HSC self-renewal in the context of the adult BM vascular niche (23) , and pathways downstream of AKT-activation in ECs, including that of nitric oxide induced by fluid shear stress, have been implicated in HSC development (49) (50) (51) . It is interesting to speculate that an AKT-induced nitric oxide pathway in the EC coculture system may circumvent the normal requirement for flow-mediated shear stress in HSC development, but further studies are required to investigate this possibility, as well as the potential role of other pathways downstream of AKT that may contribute to HSC generation in this system.
One pathway active in the AGM vascular niche, with an essential role in HSC genesis, is that of the NOTCH family (25) . Loss-offunction studies firmly established that the NOTCH pathway is required for HSC development (26) (27) (28) 31) , though recent studies suggest multiple stage-, context-, and receptor-specific functions of the NOTCH pathway in sequential processes during HSC development, including determination of arterial endothelial fate, specification of HE within lateral plate mesoderm, induction of
Discussion
Here, we examined the capacity of the vascular niche to support embryonic HSC genesis, a complex process with developmentally unique requirements to promote both the specification of engrafting HSCs from nonengrafting precursors and subsequent selfrenewal of the nascent, embryonic HSCs. We demonstrate that ECs from the AGM region are able to support robust and reproducible in vitro induction of adult-engrafting HSCs from HE and subsequently significantly expand long-term, engrafting HSC numbers dependent on NOTCH signaling ( Figure 7A ). We further identify conditions involving NOTCH signaling activation by immobilized ligand to amplify the nascent AGM-derived HSC population in the absence of EC stroma ( Figure 7B) . Importantly, these studies establish methodology to support both HSC induction and numerical expansion ex vivo from embryonic precursors, and begin to dissect critical mechanistic components of the vascular niche necessary and sufficient for this process.
Previous studies have shown that culture of whole AGM explants or reaggregated AGM stroma ex vivo can support HSC amplification from E11 embryos (15, 16, 41) . Numerous stromal cell lines derived from the AGM with various properties of mesenchymal cells have been shown to support HSC maintenance in vitro, though these studies did not demonstrate the capacity of these stromal lines to promote significant numerical expansion of AGM-derived HSCs comparable to that of reaggregation culture (18, 19) . Thus, the precise microenvironmental components within the AGM capable of supporting embryonic HSC expansion at this stage have remained unclear. While it is likely that multiple stromal cell types from the AGM microenvironment contribute to supporting embryonic HSCs, here we have shown that in vitro culture with AGM-derived ECs is sufficient to recapitulate robust amplification of HSCs from E11 VE-cadherin was dissected by removing the rostral and caudal portions of the embryo. Dissected AGM/P-Sp tissues were pooled and treated with 0.25% collagenase (StemCell Technologies Inc.) for 25-30 minutes at 37°C, pipetted to single-cell suspension, and washed with PBS containing 10% FBS. Cells were incubated with anti-mouse CD16/CD32 (FcγRII block) and stained with the following monoclonal antibodies: FITC or APC-conjugated CD45 (clone 30-F11); FITC or APC-conjugated anti-c-KIT (clone 2B8; eBioscience); FITC-, Alexa Fluor 488-, or APC-conjugated CD41 (clone MWReg30; eBioscience); unconjugated or PE-conjugated VE-cadherin/CD144 (clone 11D4.1); or corresponding isotype controls. When staining with unconjugated CD144, following incubation with primary antibodies, cells were washed twice with PBS/FBS, and secondary staining was performed with PE-conjugated mouse anti-rat IgG2a (clone RG7/1.30). All antibodies were from BD Biosciences unless otherwise indicated. DAPI staining was used to gate out dead cells. All reagents for cell staining were diluted in PBS with FBS, and staining was carried out on ice or at 4°C. Cells were sorted on a BD FACS Aria II (BD Biosciences). EC generation and culture. For derivation of AGM ECs, P-Sp/ AGM tissues were dissected from E10-E11 embryos and sorted using VE-cadherin/CD144 (clone 11D4.1), as described previously, with APC-conjugated CD45 (clone 30-F11) -along with CD41 (clone MWReg30, eBioscience) in some experiments -to exclude hematopoietic cells. Sorted cells pooled from multiple P-Sp/AGM were cultured on 48-well tissue culture plates (>20,000 VE-cadherin In some experiments, AGM AKT-ECs were cultured alone with serumHSCs from HE in the dorsal aorta, and survival of HSCs in the fetal liver (32, (52) (53) (54) (55) (56) (57) . In addition to such roles in promoting cell fate and survival, context-specific NOTCH activation is known to regulate stem/progenitor self-renewal in some systems by inhibiting lineage-specific differentiation. In this way, NOTCH2 regulates the regeneration of multipotent progenitors and HSCs in the adult BM following injury, even though canonical NOTCH signaling may be dispensable for HSCs in adult BM during homeostasis (33, 34) . Thus, ligand-mediated NOTCH activation in developing HSCs and their precursors may compose a critical component of the AGM vascular niche by limiting the differentiation of nascent HSCs as they emerge, and -in concert with other growth-factor signals -mediating their self-renewal and proliferative expansion. Consistent with this hypothesis, our studies have determined in vitro conditions whereby NOTCH activation can increase long-term engrafting HSC numbers from the newly specified E11 AGM (CD45 + VE-cadherin + ) hematopoietic cells. Although Delta1 was used as the ligand to activate the NOTCH pathway in these studies, multiple NOTCH ligands are expressed on AGM ECs, and our preliminary studies suggest that immobilized JAG1 and either NOTCH1 or NOTCH2 receptor-specific activation can also support AGM HSCs at this stage, though perhaps with different efficiencies (not shown). Additional studies will be required to determine whether the strength of NOTCH pathway activation mediated by differential-receptor activation may contribute in mediating self-renewal verses alternative cell fates in this regard.
Although NOTCH signaling is required during the HE-to-HSC transition, neither the use of immobilized NOTCH ligand under conditions that we showed could amplify HSCs from E11 AGM hematopoietic cells, nor the use of OP9 stroma expressing NOTCH ligands, was sufficient to induce engrafting HSC from HE. Further studies of AGM AKT-ECs may elucidate the nature of additional signals required for induction of HSCs from HE in concert with NOTCH pathway activation. We anticipate that such studies, by defining the precise signals necessary and sufficient in vitro for both specification and self-renewal of HSCs from embryonic precursors, will move us closer to the goal of bringing pluripotent stem cell technologies to therapeutic applications for HSC transplantation.
Methods
Mice. WT C57Bl6/J7 (Ly5.2/CD45.2) and congenic C57BL/6.SJLLy5.1-Pep3b (Ly5.1/CD45.1) mice were bred at the Fred Hutchinson Cancer Research Center. C57Bl6/J7 Ly5.2 male and female mice were used for timed matings.
Embryo dissections and cell sorting. Embryos were harvested from pregnant females, dissected free of maternal tissue, and washed extensively in PBS containing 10% FBS. Embryo age was precisely timed by counting sp. The following stages were used for studies as indicated: E9, 13-20 sp; E9.5-E10, 21-32 sp; and E11, 41-47 sp. For AGM dissections, 30-gauge needles were used to remove the caudal and rostral portions of the embryo above the forelimbs and below the hindlimbs, and subsequently to dissect off the dorsal somite tissue and ventral abdominal contents. The embryo was then splayed open lying on its dorsal surface, and remaining tissues surrounding the urogenital ridges were further dissected, leaving the intact AGM containing the dorsal aorta centrally. For embryos prior to E10, the P-Sp region jci. , and recombinant hematopoietic cytokines (PeproTech): SCF, FL, interleukin-6 (IL-6) at 100 ng/ml, and TPO at 20 ng/ml; some initial experiments also included recombinant interleukin-11 (IL-11) at 10 ng/ml and IL-3 at 100 ng/ml, though these cytokines were excluded in later experiments, as they did not improve engraftment of cultured cells. For experiments examining the effect of TGF-β1, cells were cultured in above media or serum-free (StemSpan; StemCell Technologies Inc.) with above cytokines and recombinant TGF-β1 (1 or 10 ng/ml; R&D systems) added as indicated. concentration showed a trend toward improved engraftment with relatively lower doses of Delta1 ext-IgG (0.5-2.5 μg/ml) (not shown), so these concentrations were used for subsequent analysis. Hematopoietic assays on secondary OP9 stromal culture. OP9 cells and OP9 cells expressing DLL1 (OP9-DL1) or DLL4 (OP9-DL4), a gift of J.C. Zuniga-Pflucker (University of Toronto, Toronto, Ontario, Canada), were cultured as previously described (59) . For lymphocyte assays, cells harvested following culture were replated onto OP9 or OP9-DL1 in OP9 media (αMEM, FBS 20%, penicillin/streptomycin) containing recombinant FLT3-L (FL, 10 ng/ml) and IL-7 (1 ng/ml). Cells were replated at 7-day intervals, or when confluent to fresh OP9 layers, and analyzed by flow cytometry at 7-day intervals for T cell (CD44, CD25, CD4, CD8), and B cell (CD19, B220) markers, using antibodies indicated below.
Cell surface analysis. Cells were harvested from freshly isolated P-Sp/AGM as described previously or pipetted from tissue-culture wells and washed with PBS with 2% FBS. Cells were preincubated with anti-mouse CD16/CD32 (FcγRII block) and then stained with various combinations of the following monoclonal antibodies for cell-surface analysis: APC-or FITC-conjugated CD45 (clone 30-F11); APC-, Alexa Fluor 488-, or FITC-conjugated CD41 (clone MWReg30; eBioscience); purified or PE-conjugated VE-cadherin/CD144 (clone 11D4.1); FITC-, PE-, or PECy7-conjugated anti-SCA1 (anti-Ly-6A/E, clone E13-161.7); jci.org Volume 125 Number 5 May 2015 PB, with each of donor myeloid (Gr-1 and/or F4/80), B cell (CD19), and T cell (CD3) engraftment detected at least 0.5% of total PB at 20 weeks after transplant. Study approval. All animal studies were conducted in accordance with the NIH guidelines for humane treatment of animals and were approved by the Institutional Animal Care and Use Committee at the Fred Hutchinson Cancer Research Center. cells obtained from harvested BM, spleen, and thymic tissues at the time of the secondary transplant -at least 16 weeks following the primary transplant. Staining for donor Ly5.2/CD45.2 with APCeFluor780-or PE-Cy7-conjugated CD45.2 (clone 104; eBioscience) was distinguished from Ly5.1/CD45.1 (recipient/rescue cells) stained with PE-Cy7 or eFlour-450-conjugated CD45.1 (clone A20; eBioscience) and myeloid and T/B lymphoid lineage determination was obtained by costaining with the monoclonal antibodies: FITC-conjugated anti-CD3 (clone 17A2); PE-conjugated F4/80 (clone BM8; eBioscience); APC-conjugated anti-CD19 (clone ID3); PerCP-conjugated GR-1 (anti-Ly6-G, clone RB6-8C5); PE-conjugated CD8 (clone 53-6.7); and PECy5-conjugated CD4 (clone RM4-5). Multilineage engraftment was defined as >5% donor (CD45.2) contribution to the PB with each of donor myeloid (Gr-1 and/or F4/80), B cell (CD19), and T cell (CD3) engraftment detected at ≥0.5% of total PB.
Statistics. For statistical analysis, 2-tailed, unpaired Student's t test was used to calculate P values unless otherwise indicated. P value <0.05 was considered significant. ELDA software (http://bioinf.wehi. edu.au/software/elda/) (60) was used for limit-dilution transplantation analysis, calculated using the fraction of mice engrafted at each dilution of starting cells expressed per embryo equivalent, where engraftment was defined as >5% donor (CD45.2) contribution to the
